NCT06818032

Brief Summary

The purpose of this study is to see how adding avocado to a breakfast meal affects blood sugar control and signals of hunger and fullness after eating. The investigators will test the effects of 3 breakfast meals on blood sugar control and signals of hunger and fullness after eating:

  1. 1.Whole-wheat bread and strawberry jam
  2. 2.Whole-wheat bread, strawberry jam, and avocado
  3. 3.Whole-wheat bread and strawberry jam (meal enriched with fat and fiber to mimic that of an avocado)

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for not_applicable healthy

Timeline
1mo left

Started Mar 2025

Typical duration for not_applicable healthy

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Mar 2025Jun 2026

First Submitted

Initial submission to the registry

February 4, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 10, 2025

Completed
19 days until next milestone

Study Start

First participant enrolled

March 1, 2025

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2026

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2026

Expected
Last Updated

March 28, 2025

Status Verified

March 1, 2025

Enrollment Period

11 months

First QC Date

February 4, 2025

Last Update Submit

March 24, 2025

Conditions

Keywords

Persea Americanablood glucoseblood insulinadiponectinleptinGLP-1appetitesatietyglucose toleranceGIPghrelinPeptide YY (PYY)glucose metabolismdietary fatsmeal challengemeal tolerance testdietary fiberglycemia

Outcome Measures

Primary Outcomes (1)

  • Diet-induced changes in postprandial glucose tolerance

    Blood glucose and insulin concentrations will be measured.

    60-minute time point, 120-minute time point, incremental area under the curve from fasting to 180-minute time point

Secondary Outcomes (1)

  • Diet-induced changes in postprandial satiety hormones

    60-minute time point, 120-minute time point, incremental area under the curve from fasting to 180-minute time point

Study Arms (3)

Negative control breakfast

OTHER

Participants will receive a breakfast with bread and jam, no avocado.

Other: Negative control

Avocado addition breakfast

EXPERIMENTAL

Participants will receive a breakfast with bread, jam, and avocado.

Other: Avocado

Fat and fiber control breakfast

ACTIVE COMPARATOR

Participants will receive a breakfast with bread and jam, no avocado. The breakfast meal will be enriched with fat and fiber to mimic that of an avocado.

Other: Fat and fiber addition

Interventions

Participants will be given a breakfast meal with 76 grams of bread and 60 grams of jam per 2000 daily calories.

Negative control breakfast
AvocadoOTHER

Participants will be given a bread and jam breakfast (76 grams of bread and 60 grams of jam per 2000 daily calories) supplemented with 84 grams of avocado per 2000 daily calories.

Avocado addition breakfast

Participants will be given a bread and jam breakfast (76 grams of bread and 60 grams of jam per 2000 daily calories) supplemented with 13 grams of fat (mix of high-oleic safflower oil, safflower oil, palm oil, and macadamia nut oil) and 5.5 grams of fiber (mix of cellulose and pectin) per 2000 daily calories.

Fat and fiber control breakfast

Eligibility Criteria

Age21 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Biological sex males or females
  • Age 21 to 65 years
  • BMI between 18.5 and 34.9 kg/m2

You may not qualify if:

  • Actively pregnant or lactating women
  • Diagnosis of prediabetes or diabetes (fasting glucose \>100 mg/dL)
  • Current diagnosis of uncontrolled hypertension (systolic BP: \>160 mmHg, diastolic BP: \>95 mmHg), may receive treatment for hypertension as long as on a stable regimen for the previous one month
  • Current diagnosis of uncontrolled hyperlipidemia (fasting total blood cholesterol \>200 mg/dL, fasting triglycerides \>200 mg/dL), may receive treatment for hyperlipidemia as long as on a stable regimen for the previous one month
  • Presence of kidney disease, liver disease, hyperthyroidism, untreated or unstable hypothyroidism, certain cancers, gastrointestinal disease, pancreatic disease, other chronic metabolic diseases or malabsorption syndromes, HIV, or inflammatory conditions (such as arthritis, asthma, Crohn's disease, inflammatory bowel disease, gout, Lupus)
  • History of bariatric or certain other surgeries related to weight control
  • Any medication used to lower blood glucose/antidiabetic medications \[including, but not limited to metformin, sulfonylureas, glucagon-like peptide-1 (GLP-1) analogues, sodium-glucose cotransporter-2 (SGL2) inhibitors, thiazolidinediones, dipeptidyl peptidase (DPP)-IV inhibitors\] as well as medications affecting weight, appetite/hunger or gut motility.
  • Smoking or use of other tobacco products (during 6 months prior to the start of the study)
  • Antibiotic use during the intervention or for 3 weeks prior to any treatment period
  • History of eating disorders or other significant food preferences that would interfere with the diet intervention (e.g., vegan lifestyle, very low-fat diets, high-protein diets)
  • Allergies or adverse reactions to study foods (e.g., gluten intolerance), or food aversions that would interfere with diet adherence
  • Body weight loss of \>10% within the last 6 months prior to study start
  • Unable or unwilling to give informed consent or communicate with study staff
  • Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol
  • Undergoing hormonal therapy of any kind, with the exception of a stable regime for the prior 6 months to study start.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinical Research Center, University of Vermont Medical Center

Burlington, Vermont, 05405, United States

RECRUITING

Related Publications (21)

  • https://hassavocadoboard.com/happenings/2023-year-in-review/.

    BACKGROUND
  • Zhu L, Huang Y, Edirisinghe I, Park E, Burton-Freeman B. Using the Avocado to Test the Satiety Effects of a Fat-Fiber Combination in Place of Carbohydrate Energy in a Breakfast Meal in Overweight and Obese Men and Women: A Randomized Clinical Trial. Nutrients. 2019 Apr 26;11(5):952. doi: 10.3390/nu11050952.

    PMID: 31035472BACKGROUND
  • Wright J. Effect of high-carbohydrate versus high-monounsaturated fatty acid diet on metabolic control in diabetes and hyperglycemic patients. Clin Nutr. 1998 Sep;17 Suppl 2:35-45. doi: 10.1016/s0261-5614(98)80016-2. No abstract available.

    PMID: 10205358BACKGROUND
  • U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2020-2025. 9th Edition.

    BACKGROUND
  • Sanchez D, Miguel M, Aleixandre A. Dietary fiber, gut peptides, and adipocytokines. J Med Food. 2012 Mar;15(3):223-30. doi: 10.1089/jmf.2011.0072. Epub 2011 Dec 19.

    PMID: 22181071BACKGROUND
  • Rocca AS, LaGreca J, Kalitsky J, Brubaker PL. Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1. Endocrinology. 2001 Mar;142(3):1148-55. doi: 10.1210/endo.142.3.8034.

    PMID: 11181530BACKGROUND
  • Qian F, Korat AA, Malik V, Hu FB. Metabolic Effects of Monounsaturated Fatty Acid-Enriched Diets Compared With Carbohydrate or Polyunsaturated Fatty Acid-Enriched Diets in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. 2016 Aug;39(8):1448-57. doi: 10.2337/dc16-0513.

    PMID: 27457635BACKGROUND
  • Pedreschi R, Uarrota V, Fuentealba C, Alvaro JE, Olmedo P, Defilippi BG, Meneses C, Campos-Vargas R. Primary Metabolism in Avocado Fruit. Front Plant Sci. 2019 Jun 26;10:795. doi: 10.3389/fpls.2019.00795. eCollection 2019.

    PMID: 31293606BACKGROUND
  • Park E, Edirisinghe I, Burton-Freeman B. Avocado Fruit on Postprandial Markers of Cardio-Metabolic Risk: A Randomized Controlled Dose Response Trial in Overweight and Obese Men and Women. Nutrients. 2018 Sep 12;10(9):1287. doi: 10.3390/nu10091287.

    PMID: 30213052BACKGROUND
  • Nansel TR, Lipsky LM, Liu A. Greater diet quality is associated with more optimal glycemic control in a longitudinal study of youth with type 1 diabetes. Am J Clin Nutr. 2016 Jul;104(1):81-7. doi: 10.3945/ajcn.115.126136. Epub 2016 May 18.

    PMID: 27194309BACKGROUND
  • Muller M, Canfora EE, Blaak EE. Gastrointestinal Transit Time, Glucose Homeostasis and Metabolic Health: Modulation by Dietary Fibers. Nutrients. 2018 Feb 28;10(3):275. doi: 10.3390/nu10030275.

    PMID: 29495569BACKGROUND
  • Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004 Oct 25;164(19):2147-55. doi: 10.1001/archinte.164.19.2147.

    PMID: 15505129BACKGROUND
  • Livesey G, Taylor R, Livesey HF, Buyken AE, Jenkins DJA, Augustin LSA, Sievenpiper JL, Barclay AW, Liu S, Wolever TMS, Willett WC, Brighenti F, Salas-Salvado J, Bjorck I, Rizkalla SW, Riccardi G, Vecchia C, Ceriello A, Trichopoulou A, Poli A, Astrup A, Kendall CWC, Ha MA, Baer-Sinnott S, Brand-Miller JC. Dietary Glycemic Index and Load and the Risk of Type 2 Diabetes: Assessment of Causal Relations. Nutrients. 2019 Jun 25;11(6):1436. doi: 10.3390/nu11061436.

    PMID: 31242690BACKGROUND
  • Ingram DK, Roth GS. Glycolytic inhibition: an effective strategy for developing calorie restriction mimetics. Geroscience. 2021 Jun;43(3):1159-1169. doi: 10.1007/s11357-020-00298-7. Epub 2020 Nov 12.

    PMID: 33184758BACKGROUND
  • Giuntini EB, Sarda FAH, de Menezes EW. The Effects of Soluble Dietary Fibers on Glycemic Response: An Overview and Futures Perspectives. Foods. 2022 Dec 6;11(23):3934. doi: 10.3390/foods11233934.

    PMID: 36496742BACKGROUND
  • Gillingham LG, Harris-Janz S, Jones PJ. Dietary monounsaturated fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors. Lipids. 2011 Mar;46(3):209-28. doi: 10.1007/s11745-010-3524-y. Epub 2011 Feb 10.

    PMID: 21308420BACKGROUND
  • Ford NA, Spagnuolo P, Kraft J, Bauer E. Nutritional Composition of Hass Avocado Pulp. Foods. 2023 Jun 28;12(13):2516. doi: 10.3390/foods12132516.

    PMID: 37444254BACKGROUND
  • FoodData Central. Avocados, raw, California. Available online: https://fdc.nal.usda.gov/fdc-app.html#/food-details/171706/nutrients

    BACKGROUND
  • FruiTrop. Close-up avocado. In FruiTrop Magazine; Loeillet, D., Imbert, E., Eds.; Cirad: Montpellier, France, 2015; pp. 1-96.

    BACKGROUND
  • Akhlaghi M. The role of dietary fibers in regulating appetite, an overview of mechanisms and weight consequences. Crit Rev Food Sci Nutr. 2024;64(10):3139-3150. doi: 10.1080/10408398.2022.2130160. Epub 2022 Oct 4.

    PMID: 36193993BACKGROUND
  • Abdul-Ghani MA, Williams K, DeFronzo R, Stern M. Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. Diabetes Care. 2006 Jul;29(7):1613-8. doi: 10.2337/dc05-1711.

    PMID: 16801587BACKGROUND

MeSH Terms

Interventions

CD36 Antigens

Intervention Hierarchy (Ancestors)

Platelet Membrane GlycoproteinsMembrane GlycoproteinsGlycoproteinsGlycoconjugatesCarbohydratesFatty Acid Transport ProteinsMembrane Transport ProteinsCarrier ProteinsProteinsAmino Acids, Peptides, and ProteinsMembrane ProteinsReceptors, Cell SurfaceReceptors, ImmunologicScavenger Receptors, Class BReceptors, ScavengerReceptors, LDLReceptors, Lipoprotein

Study Officials

  • Jana Kraft, Ph.D.

    University of Vermont

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Clinical Research Project Manager

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

February 4, 2025

First Posted

February 10, 2025

Study Start

March 1, 2025

Primary Completion

February 1, 2026

Study Completion (Estimated)

June 1, 2026

Last Updated

March 28, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations